Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells
Melanoma cells addicted to mutated BRAF oncogene activity can be targeted by specific kinase inhibitors until they develop resistance to therapy. We observed that the expression of Galectin-1 (Gal-1), a soluble ligand of Neuropilin-1 (NRP1), is upregulated in melanoma tumor samples and melanoma cell...
Main Authors: | Sabrina Rizzolio, Simona Corso, Silvia Giordano, Luca Tamagnone |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/8/2218 |
Similar Items
-
MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1
by: Xu D, et al.
Published: (2016-11-01) -
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
by: Xinqi Wu, et al.
Published: (2018-07-01) -
BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells
by: Patryk Górniak, et al.
Published: (2020-08-01) -
SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia
by: Elisabetta Valentini, et al.
Published: (2021-04-01) -
La gastrine et la galectine 1 modifient les propriétés biologiques des mélanomes cutanés/ Gastrin and galectin-1 modify the biological properties of cutaneous melanoma
by: Mathieu, Véronique
Published: (2007)